| ［1］ |
Johnson RW, Alvarez⁃Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective［J］. Ther Adv Vaccines, 2015,3（4）:109⁃120. doi: 10.1177/2051013615599151.<br />
|
| ［2］ |
Werner RN, Nikkels AF, Marinovic B, et al. European consensus⁃based （S2k） guideline on the management of herpes zoster ⁃ guided by the European dermatology forum （EDF） in cooperation with the European academy of dermatology and venereology （EADV）, Part 2: treatment［J］. J Eur Acad Dermatol Venereol, 2017,31（1）:20⁃29. doi: 10.1111/jdv.13957.<br />
|
| ［3］ |
中国医师协会皮肤科医师分会带状疱疹专家共识工作组. 带状疱疹中国专家共识［J］. 中华皮肤科杂志, 2018,51（6）:403⁃408. doi：10.3760/cma.j.issn.0412⁃4030.2018.06.001.<br />
|
| ［4］ |
Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster［J］. J Microbiol Immunol Infect, 2001,34（2）:138⁃142.<br />
|
| ［5］ |
Gopal MG, Shannoma, Kumar BCS, et al. A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster［J］. J Clin Diagn Res, 2013,7（12）:2904⁃2907. doi: 10.7860/JCDR/2013/7884.3670.<br />
|
| ［6］ |
Ono F, Yasumoto S, Furumura M, et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster［J］. J Dermatol, 2012,39（11）:902⁃908. doi: 10.1111/j.1346⁃8138.2012.01584.x.<br />
|
| ［7］ |
Yaldiz M, Solak B, Kara RO, et al. Comparison of famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with herpes zoster［J］. Am J Ther, 2016. ［published online ahead of print Jan 20, 2016］. doi: 10.1097/MJT. 0000000000000436.<br />
|
| ［8］ |
Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia［DB/OL］. Cochrane Database Syst Rev, 2014,（2）:CD006866. doi: 10.1002/14651858.CD006866.pub3.<br />
|
| ［9］ |
Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia［J］. Antiviral Res, 2003,59（1）:57⁃60.<br />
|
| ［10］ |
Lewis DJ, Schlichte MJ, Dao H. Atypical disseminated herpes zoster: management guidelines in immunocompromised patients［J］. Cutis, 2017,100（5）:321;324;330.<br />
|
| ［11］ |
Kuchar E, Szenborn L, Lis I, et al. Clinical presentation of herpes zoster in immunocompetent and immunocompromised hospita⁃lized children treated with acyclovir［J］. J Pediatr Hematol Oncol, 2016,38（5）:394⁃397. doi: 10.1097/MPH.0000000000000567.<br />
|
| ［12］ |
Tyring SK, Lee P, Hill GT, et al. FV⁃100 versus valacyclovir for the prevention of post⁃herpetic neuralgia and the treatment of acute herpes zoster⁃associated pain: a randomized⁃controlled trial［J］. J Med Virol, 2017,89（7）:1255⁃1264. doi: 10.1002/jmv.24750.<br />
|
| ［13］ |
Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without pre⁃dnisolone for treatment of acute herpes zoster［J］. N Engl J Med, 1994,330（13）:896⁃900. doi: 10.1056/NEJM199403313301304.<br />
|
| ［14］ |
Luyten J, Ogunjimi B, Beutels P. Varicella⁃zoster virus vaccination under the exogenous boosting hypothesis: two ethical perspectives［J］. Vaccine, 2014,32（52）:7175⁃7178. doi: 10.1016/j.vaccine. 2014.10.015.<br />
|
| ［15］ |
Levin MJ. Varicella⁃zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella⁃zoster virus infections［J］. J Clin Virol, 2014,61（4）:487⁃495. doi: 10.1016/j.jcv.2014.09.012.<br />
|
| ［16］ |
Voros J, Koyfman A, Foran M. Do corticosteroids prevent postherpetic neuralgia?［J］. Ann Emerg Med, 2014,63（3）:351⁃352. doi: 10.1016/j.annemergmed.2013.08.010.<br />
|
| ［17］ |
Han Y, Zhang J, Chen N, et al. Corticosteroids for preventing postherpetic neuralgia［DB/OL］. Cochrane Database Syst Rev, 2013,（3）:CD005582. doi: 10.1002/14651858.CD005582.pub4.<br />
|
| ［18］ |
Pleyer U, Chee SP. Current aspects on the management of viral uveitis in immunocompetent individuals［J］. Clin Ophthalmol, 2015,9:1017⁃1028. doi: 10.2147/OPTH.S60394.<br />
|
| ［19］ |
Montague SJ, Morton AR. Ramsay Hunt syndrome［J］. CMAJ, 2017,189（8）:E320. doi: 10.1503/cmaj.160483.<br />
|
| ［20］ |
American College of Obstetricians and Gynecologists. Practice bulletin no. 151: cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy［J］. Obstet Gynecol, 2015,125（6）:1510⁃1525. doi: 10.1097/01.AOG.0000466430.19823.53.<br />
|
| ［21］ |
Aarnisalo J, Ilonen J, Vainionpää R, et al. Development of antibodies against cytomegalovirus, varicella⁃zoster virus and herpes simplex virus in Finland during the first eight years of life: a prospective study［J］. Scand J Infect Dis, 2003,35（10）:750⁃753.<br />
|
| ［22］ |
Civen R, Marin M, Zhang J, et al. Update on incidence of herpes zoster among children and adolescentsafter implementation of varicella vaccination, Antelope Valley, CA, 2000 to 2010［J］. Pediatr Infect Dis J, 2016,35（10）:1132⁃1136. doi: 10.1097/INF.0000000000001249.<br />
|
| ［23］ |
Katakam BK, Kiran G, Kumar U. A prospective study of herpes zoster in children［J］. Indian J Dermatol, 2016,61（5）:534⁃539. doi: 10.4103/0019⁃5154.190121.<br />
|
| ［24］ |
Peterson N, Goodman S, Peterson M, et al. Herpes zoster in children［J］. Cutis, 2016,98（2）:94⁃95.<br />
|
| ［25］ |
带状疱疹后神经痛诊疗共识编写专家组. 带状疱疹后神经痛诊疗中国专家共识［J］. 中国疼痛医学杂志, 2016,22（3）:161⁃167.<br />
|
